AML modalities, such as DNA damaging agents and receptor kinase inhibitors, converge to dephosphorylate rpS6 through their actions on the akt/mTOR, ATM/AMPK/mTOR and ERK pathways, suggesting that further research in this area could be fruitful. Here, RPS6 is linked to acute myeloid leukemia.